How Well Are We Measuring Nausea? A Narrative Review of Patient-Reported Outcome Gaps in GLP-1 Receptor Agonist Obesity Trials. (PubMed, Diabetes Obes Metab) - Oct 25, 2026 - "This narrative review traces how nausea was actually measured across the pivotal liraglutide (SCALE), semaglutide (STEP) and tirzepatide (SURMOUNT) obesity trial programmes, and situates those methods against the standards set out in the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) and the United States Food and Drug Administration's Patient-Focused Drug Development guidance. This observation gains further importance when considered alongside a second, less widely recognized fact: these same trial programmes devoted substantial methodological effort to developing and implementing a rigorous, quality of life measure specifically for obesity, the Impact of Weight on Quality of Life-Lite Clinical Trials Version in addition to the Short Form-36 and EuroQol-5D. We argue that this asymmetry, more than any single mismeasurement, helps explain why real-world persistence with these agents falls so far short of what..."
Journal • Review • Genetic Disorders • Obesity
|
|
Lima Oria; Mohammad Darkhabani
|